整合临床评估痣与日光性黑子的黑色素瘤风险预测模型开发与外部验证
基于澳大利亚黑色素瘤家族研究(461例病例和329例对照)开发了包含临床评估全身痣数、上背部日光性黑子、18岁时发色及个人角质形成细胞癌史的首次原发性皮肤黑色素瘤风险预测模型,并在英国Leeds病例对照研究(960例病例和513例对照)中进行外部验证。
要点
- 模型纳入全身直径≥2mm痣数、上背部日光性黑子、18岁时发色及角质形成细胞癌史。
- 模型区分度良好,可用于临床分层患者黑色素瘤风险以匹配预防干预。
核心结论
- 该模型区分度良好,临床医生可用于对患者进行黑色素瘤风险分层,以针对性开展预防干预。
研究设计与样本
- 澳大利亚黑色素瘤家族研究(461例病例和329例对照)用于开发模型,采用非条件logistic回归后退法,年龄、性别和招募城市强制保留。
- Leeds黑色素瘤病例对照研究(960例病例和513例对照)用于外部验证。
- 候选预测因子包括临床评估的全身痣和日光性黑子,以及自评的色素表型、日晒、家族史和角质形成细胞癌史。
主要发现
- 最终模型包含全身直径≥2mm的痣数、上背部日光性黑子(六级量表)、18岁时发色和个人角质形成细胞癌史。
临床怎么用
- 临床医生可使用该模型,基于临床评估的痣数、日光性黑子、发色和角质形成细胞癌史对患者进行黑色素瘤风险分层。
- 根据风险分层结果,可针对性匹配预防干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melanoma risk prediction models could be useful for matching preventive interventions to patients' risk. OBJECTIVES: To develop and validate a model for incident first-primary cutaneous melanoma using clinically assessed risk factors. METHODS: We used unconditional logistic regression with backward selection from the Australian Melanoma Family Study (461 cases and 329 controls) in which age, sex and city of recruitment were kept in each step, and we externally validated it using the Leeds Melanoma Case-Control Study (960 cases and 513 controls). Candidate predictors included clinically assessed whole-body naevi and solar lentigines, and self-assessed pigmentation phenotype, sun exposure, family history and history of keratinocyte cancer. We evaluated the predictive strength and discrimination of the model risk factors using odds per age- and sex-adjusted SD (OPERA) and the area under curve (AUC), and calibration using the Hosmer-Lemeshow test. RESULTS: The final model included the number of naevi ≥ 2 mm in diameter on the whole body, solar lentigines on the upper back (a six-level scale), hair colour at age 18 years and personal history of keratinocyte cancer. Naevi was the strongest risk factor; the OPERA was 3·51 [95% confidence interval (CI) 2·71-4·54] in the Australian study and 2·56 (95% CI 2·23-2·95) in the Leeds study. The AUC was 0·79 (95% CI 0·76-0·83) in the Australian study and 0·73 (95% CI 0·70-0·75) in the Leeds study. The Hosmer-Lemeshow test P-value was 0·30 in the Australian study and < 0·001 in the Leeds study. CONCLUSIONS: This model had good discrimination and could be used by clinicians to stratify patients by melanoma risk for the targeting of preventive interventions. What's already known about this topic? Melanoma risk prediction models may be useful in prevention by tailoring interventions to personalized risk levels. For reasons of feasibility, time and cost many melanoma prediction models use self-assessed risk factors. However, individuals tend to underestimate their naevus numbers. What does this study add? We present a melanoma risk prediction model, which includes clinically-assessed whole-body naevi and solar lentigines, and self-assessed risk factors including pigmentation phenotype and history of keratinocyte cancer. This model performs well on discrimination, the model's ability to distinguish between individuals with and without melanoma, and may assist clinicians to stratify patients by melanoma risk for targeted preventive interventions.
引用
- Vuong K, Armstrong BK, Drummond M, et al. Development and external validation study of a melanoma risk prediction model incorporating clinically assessed naevi and solar lentigines. Br J Dermatol. 2019. PMID: 31378928. doi:10.1111/bjd.18411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。